AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34581002 — intervention group
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Number of subjects: 106
Study 34797296 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaobei injection
Number of subjects: 0
Study 34797296 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 0
Study 33152708 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 0
Study 33152708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36368980 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based tool (CatInfo)
Number of subjects: 134
Study 33557701 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser extirpation with methyl aminolevulinate photodynamic therapy
Number of subjects: 100
Study 35294595 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) performed by trained personnel, consisting of four cycles of limb ischemia (4-min via cuff inflation) followed by reperfusion (4-min via cuff deflation), repeated on two consecutive days post randomization.
Number of subjects: 78
Study 35294595 — intervention group
Group type: COMPARATOR
Intervention: No remote ischemic conditioning (no-RIC) as control group, continuing standard management of NEC.
Number of subjects: 78
Study 32857442 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal knowledge about child development and caregiving
Number of subjects: 1277
Study 32857442 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal engagement in stimulating activities with the child
Number of subjects: 1277
Study 36239563 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Cycle of Breathing Technique (ACBT) with Watson's Theory of Human Caring
Number of subjects: 64
Study 36239563 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 64
Study 34657371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES) at 10 mL/kg
Number of subjects: 23
Study 34657371 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline 7.5% (HS) at 4 mL/kg
Number of subjects: 23
Study 34657371 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HES and HS
Number of subjects: 23
Study 32538466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 5 mg kg‐1 per day
Number of subjects: 200
Study 32538466 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin 10 mg kg‐1 per day
Number of subjects: 200
Study 32538466 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 5 mg kg‐1 per day
Number of subjects: 200
Study 32538466 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 7·5 mg kg‐1 per day
Number of subjects: 200
Study 34238688 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 Gy single-fraction HDR brachytherapy
Number of subjects: 31
Study 34238688 — intervention group
Group type: COMPARATOR
Intervention: Iodine-125 Low-Dose-Rate brachytherapy
Number of subjects: 31
Study 34033513 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaCom rehabilitation software (ten 45‐min sessions across five weeks, two sessions per week)
Number of subjects: 50
Study 34033513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 32272962 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally collected patient-reported outcome measures (PROMs)
Number of subjects: 0
Study 32272962 — intervention group
Group type: COMPARATOR
Intervention: Standard care without PROMs
Number of subjects: 0
Study 32657670 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrodia cinnamomea mycelium (ACM), 420 mg, three capsules per day for 6 months
Number of subjects: 28
Study 32657670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch), 420 mg, three capsules per day for 6 months
Number of subjects: 28
Study 32489001 — intervention group
Group type: EXPERIMENTAL
Intervention: tongue‐hold swallowing
Number of subjects: 74
Study 32489001 — intervention group
Group type: EXPERIMENTAL
Intervention: tongue‐pressure resistance training
Number of subjects: 74
Study 32489001 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 74
Study 35840352 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo Ventilation (ASV)
Number of subjects: 312
Study 35840352 — intervention group
Group type: COMPARATOR
Intervention: Control (guideline-based medical therapy)
Number of subjects: 312
Study 34076919 — intervention group
Group type: EXPERIMENTAL
Intervention: brodalumab
Number of subjects: 0
Study 34076919 — intervention group
Group type: COMPARATOR
Intervention: ustekinumab
Number of subjects: 0
Study 34929392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarcane bagasse diet (33 g/d fiber)
Number of subjects: 26
Study 34929392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber combination diet (sugarcane bagasse with resistant starch, 45 g/d fiber)
Number of subjects: 26
Study 33154288 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual aid and face-to-face interactive sessions
Number of subjects: 166
Study 33154288 — intervention group
Group type: COMPARATOR
Intervention: Pamphlets alone
Number of subjects: 166
Study 36262203 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqisuxin granule (SQSX) for 2 months
Number of subjects: 120
Study 36262203 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 120
Study 36262203 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqisuxin granule (SQSX)
Number of subjects: 120
Study 36262203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33002647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with reduced treatment volumes (50.4 Gy total radiation dose, fluoropyrimidine‐based chemotherapy)
Number of subjects: 52
Study 33002647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with reduced treatment volumes
Number of subjects: 52
Study 35831757 — intervention group
Group type: EXPERIMENTAL
Intervention: Key feature format (test-enhanced learning)
Number of subjects: 94
Study 35831757 — intervention group
Group type: COMPARATOR
Intervention: Read-only cases
Number of subjects: 94
Study 34645411 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐ACTIVE EAT (low intensity prophylactic intervention)
Number of subjects: 952
Study 34645411 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐ACTIVE EAT+EXERCISE (high intensity prophylactic intervention)
Number of subjects: 952
Study 34645411 — intervention group
Group type: COMPARATOR
Intervention: RE‐ACTIVE (started promptly if/when dysphagia is identified)
Number of subjects: 952
Study 34645411 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes include objective measures of swallow physiology and function, pneumonia and weight loss, quality of life, symptom burden, and self-efficacy.
Number of subjects: 952
Study 33232794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (70 steps per minute)
Number of subjects: 10
Study 33232794 — intervention group
Group type: EXPERIMENTAL
Intervention: Housework (at the same intensity as aerobic exercise)
Number of subjects: 10
Study 33232794 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary)
Number of subjects: 10
Study 33232794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 10
Study 33232794 — intervention group
Group type: EXPERIMENTAL
Intervention: Housework
Number of subjects: 10
Study 33232794 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 35606229 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program for 3 days a week over 6 weeks (T1-T2)
Number of subjects: 30
Study 35606229 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program for 3 days a week over 6 weeks (T2-T3)
Number of subjects: 30
Study 33650767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) session per month and three home exercise sessions per week for four months
Number of subjects: 19
Study 33650767 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study 32060991 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant conditioning
Number of subjects: 0
Study 32060991 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 33947363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate treatment for osteoporosis alone (Group 1)
Number of subjects: 159
Study 33947363 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate treatment for osteoporosis with symptomatic LSS (Group 2)
Number of subjects: 159
Study 33176700 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted HIV self-testing (UH)
Number of subjects: 0
Study 33176700 — intervention group
Group type: COMPARATOR
Intervention: Directly assisted HIV self-testing (DAH)
Number of subjects: 0
Study 34742917 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-interventional approach for medication safety (MIMS) including medication reconciliation at admission and discharge, medication review, and standardized transmission of medication changes to community practitioners.
Number of subjects: 109
Study 34742917 — intervention group
Group type: COMPARATOR
Intervention: Usual approach applied in the AGU (control group).
Number of subjects: 109
Study 34742917 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-interventional approach for medication safety (MIMS)
Number of subjects: 109
Study 34073277 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention
Number of subjects: 268
Study 34073277 — intervention group
Group type: COMPARATOR
Intervention: Attention control telephone intervention
Number of subjects: 268
Study 34073277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 268
Study 35170724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis and self-hypnosis (8 sessions) combined with standard nutritional education (8 workshops)
Number of subjects: 82
Study 35170724 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional education (8 workshops)
Number of subjects: 82
Study 35170724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis and self-hypnosis
Number of subjects: 82
Study 34550939 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan Hand Outcomes Questionnaire
Number of subjects: 0
Study 33393650 — intervention group
Group type: EXPERIMENTAL
Intervention: SpiroTimer™
Number of subjects: 52
Study 33876525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month structured bronchoscopy curriculum with simulator training
Number of subjects: 18
Study 33876525 — intervention group
Group type: COMPARATOR
Intervention: Traditional apprenticeship training
Number of subjects: 18
Study 32178928 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 109
Study 32178928 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with inhaled anesthetic
Number of subjects: 109
Study 32178928 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 109
Study 34979544 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU of intranasal oxytocin (IN-OT)
Number of subjects: 19
Study 34979544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 19
Study 33742783 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic (PopPK) approach
Number of subjects: 100
Study 33742783 — intervention group
Group type: COMPARATOR
Intervention: Noncompartmental analysis (NCA) approach
Number of subjects: 100
Study 33446373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound bladder vibrometry (UBV) in supine position
Number of subjects: 8
Study 33446373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound bladder vibrometry (UBV) in sitting position
Number of subjects: 8
Study 33446373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound bladder vibrometry (UBV) in both positions
Number of subjects: 8
Study 32519235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (SE)
Number of subjects: 1120
Study 32519235 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive (U)
Number of subjects: 1120
Study 32519235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1120
Study 35879015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery and intensive goal-directed medical therapy
Number of subjects: 150
Study 35879015 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery and standard medical care
Number of subjects: 150
Study 33504953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily)
Number of subjects: 1879
Study 33504953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1879
Study 32194251 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 298
Study 32194251 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 298
Study 35367059 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Morphological Assessment (CMA)
Number of subjects: 139
Study 35367059 — intervention group
Group type: COMPARATOR
Intervention: Time-Lapse Monitoring (TLM)
Number of subjects: 139
Study 35367059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Embryo Transfer (CMA)
Number of subjects: 139
Study 35367059 — intervention group
Group type: COMPARATOR
Intervention: Fresh Embryo Transfer (TLM)
Number of subjects: 139
Study 35367059 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen Embryo Transfer (CMA)
Number of subjects: 139
Study 35367059 — intervention group
Group type: COMPARATOR
Intervention: Frozen Embryo Transfer (TLM)
Number of subjects: 139
Study 33761182 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration between registered nurses (RNs) and general practitioners (GPs)
Number of subjects: 35
Study 33761182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of care provided by existing GPs for new residents
Number of subjects: 35
Study 33761182 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to medication management systems
Number of subjects: 35
Study 33761182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of family in the care team
Number of subjects: 35
Study 33761182 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational continuity of care
Number of subjects: 35
Study 35938229 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD Fibrosis Index (NFI) model
Number of subjects: 309
Study 34368187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg intravenous)
Number of subjects: 24
Study 34368187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 34368187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg intravenous) during hypoxia
Number of subjects: 24
Study 34368187 — intervention group
Group type: COMPARATOR
Intervention: Placebo during hypoxia
Number of subjects: 24
Study 33046128 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoction + Moxibustion (MD)
Number of subjects: 462
Study 33046128 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Moxibustion (MP)
Number of subjects: 462
Study 34417198 — intervention group
Group type: EXPERIMENTAL
Intervention: tivozanib 1.34 mg orally once daily for 21 consecutive days of every 28‐day cycle
Number of subjects: 0
Study 34417198 — intervention group
Group type: COMPARATOR
Intervention: sorafenib 400 mg orally twice daily continuously
Number of subjects: 0
Study 34417198 — intervention group
Group type: EXPERIMENTAL
Intervention: tivozanib
Number of subjects: 0
Study 33952544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (SM) intervention as part of a non-blinded block-randomised controlled trial (RCT) with assessments at T1, T2, T3, and T4.
Number of subjects: 526
Study 33952544 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care without the SM intervention.
Number of subjects: 526
Study 35659622 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 480
Study 35659622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 36250677 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model for blood pixel classification
Number of subjects: 3
Study 36250677 — intervention group
Group type: COMPARATOR
Intervention: Control group (low skill and novice surgeons)
Number of subjects: 3
Study 33203433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health promotion intervention (3 individual sessions of 1 hour)
Number of subjects: 72
Study 33203433 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 72
Study 33766814 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate (MPA) 400 mg intramuscularly on day 1
Number of subjects: 50
Study 33766814 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone Acetate (MPA) 400 mg intramuscularly on day 1 plus Entinostat 5 mg orally on days 1, 8, and 15
Number of subjects: 50
Study 32543450 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking among university students
Number of subjects: 4599
Study 32543450 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical and non-health colleges
Number of subjects: 4599
Study 32543450 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 4599
Study 36154103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with statin and ezetimibe
Number of subjects: 2860
Study 36154103 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin monotherapy
Number of subjects: 2860
Study 36154103 — intervention group
Group type: COMPARATOR
Intervention: Higher target group (LDL cholesterol of 100±10 mg/dL)
Number of subjects: 2860
Study 36441246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronch®AP palatal device
Number of subjects: 22
Study 36441246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 32640956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek vaginal cream 5% (0.5g, twice a week for 12 weeks)
Number of subjects: 60
Study 32640956 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens vaginal cream (0.625 mg, containing 0.3 mg of conjugated estrogens)
Number of subjects: 60
Study 36088292 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of MATRix (control treatment)
Number of subjects: 326
Study 36088292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-phase (R/HD-MTX) followed by 2 cycles of MATRix (experimental treatment)
Number of subjects: 326
Study 32639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib, 130 mg/d
Number of subjects: 12092
Study 32639518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12092
Study 32639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 12092
Study 33711136 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defects with clips
Number of subjects: 401
Study 33711136 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of mesenteric defects
Number of subjects: 401
Study 33711136 — intervention group
Group type: COMPARATOR
Intervention: Closure of mesenteric defects with clips and Non-closure of mesenteric defects
Number of subjects: 401
Study 32804742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg daily added to ongoing antidepressant therapy
Number of subjects: 0
Study 32804742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 616926927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg IV
Number of subjects: 50
Study 616926927 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 1 mg/kg IV
Number of subjects: 50
Study 34273258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of metformin hydrochloride/vildagliptin 850 mg/50 mg (test preparation)
Number of subjects: 30
Study 34273258 — intervention group
Group type: COMPARATOR
Intervention: Branded product of metformin hydrochloride/vildagliptin 850 mg/50 mg (reference preparation)
Number of subjects: 30
Study 34273258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (test and reference)
Number of subjects: 30
Study 33337821 — intervention group
Group type: EXPERIMENTAL
Intervention: NPTQ short form (NPTQ-SF)
Number of subjects: 137
Study 33337821 — intervention group
Group type: EXPERIMENTAL
Intervention: NPTQ
Number of subjects: 137
Study 33337821 — intervention group
Group type: COMPARATOR
Intervention: NPTQ and NPTQ-SF
Number of subjects: 137
Study 33346814 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT injection
Number of subjects: 30
Study 33966115 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy doses > 40 Gy
Number of subjects: 53
Study 33966115 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy doses > 50 Gy
Number of subjects: 53
Study 33966115 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy doses > 60 Gy
Number of subjects: 53
Study 34715031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (900 mg daily for 6 months)
Number of subjects: 985
Study 34715031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985
Study 34715031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (in patients without asymptomatic gallstones)
Number of subjects: 985
Study 34715031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (in patients undergoing RYGB)
Number of subjects: 985
Study 34715031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 985
Study 32087694 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive dual-task training with variable- to fixed-priority instructions
Number of subjects: 60
Study 32087694 — intervention group
Group type: COMPARATOR
Intervention: Dual-task training with variable-priority attention exercises
Number of subjects: 60
Study 34378087 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV 2μg
Number of subjects: 245
Study 34378087 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV 4μg
Number of subjects: 245
Study 34378087 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV 6μg
Number of subjects: 245
Study 34378087 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV 8μg
Number of subjects: 245